Akebia Therapeutics' Series B - II Round

Akebia Therapeutics raised a round of funding on January 09, 2012.

Akebia Therapeutics is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia's lead product candidate, vadadustat, is an inv…

Articles about Akebia Therapeutics' Series B - II Round: